A Phenotypic Approach to the Discovery of Potent G-Quadruplex Targeted Drugs
Molecules · 01.08.2024 · 29 (15) · 3653
DOI: 10.3390/molecules29153653 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 01.08.2024. Verfasst von Stephen Neidle. Beteiligte Einrichtung: The School of Pharmacy, University College London, London WC1N 1AX, UK. Hauptthemen laut MEDLINE: G-Quadruplexes, Drug Discovery, Antineoplastic Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research Campaign, The Medical Research Council, Wellcome Trust.
Abstract (Originalsprache)
G-quadruplex (G4) sequences, which can fold into higher-order G4 structures, are abundant in the human genome and are over-represented in the promoter regions of many genes involved in human cancer initiation, progression, and metastasis. They are plausible targets for G4-binding small molecules, which would, in the case of promoter G4s, result in the transcriptional downregulation of these genes. However, structural information is currently available on only a very small number of G4s and their ligand complexes. This limitation, coupled with the currently restricted information on the G4-containing genes involved in most complex human cancers, has led to the development of a phenotypic-led approach to G4 ligand drug discovery. This approach was illustrated by the discovery of several generations of tri- and tetra-substituted naphthalene diimide (ND) ligands that were found to show potent growth inhibition in pancreatic cancer cell lines and are active in in vivo models for this hard-to-treat disease. The cycles of discovery have culminated in a highly potent tetra-substituted ND derivative, QN-302, which is currently being evaluated in a Phase 1 clinical trial. The major genes whose expression has been down-regulated by QN-302 are presented here: all contain G4 propensity and have been found to be up-regulated in human pancreatic cancer. Some of these genes are also upregulated in other human cancers, supporting the hypothesis that QN-302 is a pan-G4 drug of potential utility beyond pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The School of Pharmacy, University College London, London WC1N 1AX, UK.
ORCID-Profile: Stephen Neidle
Förderung
- Cancer Research Campaign
- The Medical Research Council
- Wellcome Trust
- Pancreatic Cancer Research Fund
- CL Technology Fund
Zitieren
APA
Neidle, S. (2024). A Phenotypic Approach to the Discovery of Potent G-Quadruplex Targeted Drugs. Molecules, 29(15), 3653. https://doi.org/10.3390/molecules29153653
Vancouver
Neidle S. A Phenotypic Approach to the Discovery of Potent G-Quadruplex Targeted Drugs. Molecules. 2024;29(15):3653. doi:10.3390/molecules29153653
BibTeX
@article{Neidle2024,
author = {Neidle, Stephen},
title = {A Phenotypic Approach to the Discovery of Potent G-Quadruplex Targeted Drugs},
journal = {Molecules},
year = {2024},
volume = {29},
number = {15},
pages = {3653},
doi = {10.3390/molecules29153653}
}
EUVIMED